Metamizol Zentiva (Metamizole Sodium Monohydrate)

Metamizole sodium works by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production. This reduction diminishes peripheral pain signaling, central pain perception, and hypothalamic temperature regulation, providing both analgesic and antipyretic effects. It also has spasmolytic activity that helps relieve visceral cramping.

The dosage of Metamizol Zentiva is determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals calculate the appropriate intravenous volume and rate according to local guidelines and individual therapeutic needs.

Safety data for Metamizole sodium in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk, and a healthcare provider must evaluate each case individually.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with traditional NSAIDs, Metamizol offers strong analgesic and antipyretic effects with a lower incidence of gastrointestinal irritation but carries a risk of rare blood dyscrasias such as agranulocytosis. Its rapid intravenous onset makes it useful for acute postoperative pain where oral agents are unsuitable.

Metamizol Zentiva should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and ensure the vial is kept sealed until use.

The medication is given by intravenous injection or infusion under the supervision of qualified healthcare personnel. The solution is typically diluted in compatible IV fluids and administered over a short period, following the prescriber’s instructions regarding rate and total dose.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Immediate medical attention is required if signs of infection, rash, breathing difficulty, or sudden hypotension occur.

Patients with known hypersensitivity to Metamizole sodium or other pyrazolones should avoid the drug. It is also contraindicated in individuals with a history of severe blood dyscrasias, uncontrolled cardiovascular instability, or those receiving concurrent myelosuppressive therapy without close monitoring.